These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7285480)

  • 1. Furosemide kinetics in patients with hepatic cirrhosis with ascites.
    Fuller R; Hoppel C; Ingalls ST
    Clin Pharmacol Ther; 1981 Oct; 30(4):461-7. PubMed ID: 7285480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of furosemide in patients with hepatic cirrhosis.
    González G; Arancibia A; Rivas MI; Caro P; Antezana C
    Eur J Clin Pharmacol; 1982; 22(4):315-20. PubMed ID: 7106167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Furosemide kinetics and dynamics in patients with cirrhosis.
    Villeneuve JP; Verbeeck RK; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1986 Jul; 40(1):14-20. PubMed ID: 3720175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial natriuretic factor, cyclic 3',5'-guanosine monophosphate and prostaglandin E2 in liver cirrhosis: relation to blood volume and changes in blood volume after furosemide.
    Jespersen B; Jensen L; Sørensen SS; Pedersen EB
    Eur J Clin Invest; 1990 Dec; 20(6):632-41. PubMed ID: 1964125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Furosemide disposition in cirrhosis.
    Verbeeck RK; Patwardhan RV; Villeneuve JP; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1982 Jun; 31(6):719-25. PubMed ID: 7075120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Furosemide disposition in cirrhotic patients.
    Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
    Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Torasemide versus furosemide in cirrhosis: a long-term, double-blind, randomized clinical study.
    Fiaccadori F; Pedretti G; Pasetti G; Pizzaferri P; Elia G
    Clin Investig; 1993 Jul; 71(7):579-84. PubMed ID: 8374255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide.
    Keller E; Hoppe-Seyler G; Mumm R; Schollmeyer P
    Eur J Clin Pharmacol; 1981; 20(1):27-33. PubMed ID: 7308269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of imidazole-salicylate on renal function and the diuretic action of furosemide in cirrhotic patients with ascites.
    Salerno F; Lorenzano E; Maggi A; Badalamenti S; Minuz P; Degan M; Chinea B; Scotti A
    J Hepatol; 1993 Sep; 19(2):279-84. PubMed ID: 8301062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.
    Gentilini P; La Villa G; Marra F; Carloni V; Melani L; Foschi M; Cotrozzi G; Quartini M; Chibbaro G; Tommasi AC; Bernareggi A; Simoni A; Buzzelli G; Laffi G
    J Hepatol; 1996 Oct; 25(4):481-90. PubMed ID: 8912147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial.
    Gerbes AL; Bertheau-Reitha U; Falkner C; Jüngst D; Paumgartner G
    J Hepatol; 1993 Mar; 17(3):353-8. PubMed ID: 8315263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamic effects of furosemide in patients with liver cirrhosis.
    Traeger A; Häntze R; Penzlin M; Krombholz B; Reinhardt M; Keil E; Jorke D
    Int J Clin Pharmacol Ther Toxicol; 1985 Mar; 23(3):129-33. PubMed ID: 3997298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure.
    Ginès A; Salmerón JM; Ginès P; Arroyo V; Jiménez W; Rivera F; Rodés J
    J Hepatol; 1993 Feb; 17(2):220-6. PubMed ID: 8445236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of furosemide on diuresis and salt diuresis, blood electrolytes concentrations in various aspects of renal function in liver cirrhotic patients with ascites].
    Bardi A; Merino I; Doerr E; Rendic Y; Generini G; Plaza de los Reyes M
    Rev Med Chil; 1968 Mar; 96(3):142-4. PubMed ID: 5732745
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of a new loop diuretic (muzolimine) in cirrhosis with ascites: comparison with furosemide.
    Bernardi M; De Palma R; Trevisani F; Santini C; Patrono D; Motta R; Servadei D; Gasbarrini G
    Hepatology; 1986; 6(3):400-5. PubMed ID: 3519416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatic cirrhosis with refractory ascitis and changes in renal function: effects of the infusion of fresh plasma and furosemide].
    Bardi A; Orozco R; Sapunar J; Fernández I
    Rev Med Chil; 1989 Jul; 117(7):740-6. PubMed ID: 2519427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of furosemide on the renal prostaglandin system in liver cirrhosis with ascites].
    Mansurov KhKh; Dustov AD
    Klin Med (Mosk); 1989 Oct; 67(10):78-81. PubMed ID: 2615314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascites kinetics in cirrhosis: effects of rapid volume expansion and diuretic administration.
    Rector WG
    J Lab Clin Med; 1988 Feb; 111(2):166-72. PubMed ID: 3339270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of effect of cimetidine on furosemide kinetics and dynamics in patients with hepatic cirrhosis.
    Sanchis Closa A; Lambert C; du Souich P
    Int J Clin Pharmacol Ther Toxicol; 1993 Sep; 31(9):461-6. PubMed ID: 8225696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of furosemide in healthy subjects and in those with renal failure.
    Beermann B; Dalén E; Lindström B
    Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.